



Downregulation of miR-143/145 Cluster in Breast Carcinoma Specimens: Putative Role of DNA Oncoviruses

Mohsen Nakhaie^{1,2}, Manoochehr Makvandi^{1,2}, Javad Charostad^{1,2}, Seyyed Ali Mohammad Arabzadeh³, Azim Motamedfar⁴ and Gholam Abbas Kaydani^{1,5,*}

¹Cancer Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

²Department of Medical Virology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

³Department of Medical Microbiology, Kerman University of Medical Sciences, Kerman, Iran

⁴Department of Nuclear Medicine, School of Medicine, Golestan Hospital, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

⁵Department of Laboratory Sciences, School of Paramedical Sciences, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

*Corresponding author: Department of Laboratory Sciences, School of Paramedical Sciences, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran. Email: kaydani-ga@ajums.ac.ir

Received 2020 November 02; Revised 2021 January 19; Accepted 2021 January 27.

Abstract

Background: The DNA oncoviruses, including human papillomavirus (HPV) and Epstein-Barr virus (EBV) are among the most important infectious agents involved in breast carcinogenesis. These oncoviruses have a broad disrupting effect on cellular miRNAs and their functions, by which they contribute to carcinogenesis.

Objectives: In this investigation, we evaluated the correlation between HPV and EBV and the expression level of tumor suppressor miRNAs (miR-143 and 145), clinical outcomes, and their association with stimulating inflammatory cytokines in patients with breast carcinoma.

Methods: In our case-control study, 35 cancerous tissues and 35 adjacent non-cancerous tissues were collected from 35 patients. Nested-PCR was set up for the detection of HPV and EBV genomes, and RT-qPCR was used for miRNA expression in the case and control groups. In addition, serum specimens were obtained from all patients (n = 35) and healthy controls (n = 35) to determine the IL-8 serum concentration.

Results: We found HPV and EBV in 14.2% (10/70) and 7% (5/70) of all samples, respectively. The distributions of positive samples in the case and control groups were 25.7% (9/35) and 2.9% (1/35) (P = 0.006) for HPV and 11.4% (4/35) and 2.9% (1/35) (P = 0.164) for EBV, respectively. Besides, RT-qPCR showed that miR-143 and miR-145 were significantly downregulated in HPV and EBV-infected cases compared to non-infected ones (P < 0.05). Data also indicated that the promotion of metastasis status was related to miR-143/145 downregulation and HPV infection (P = 0.003). No significant difference was found in serum IL-8 concentration concerning viral infections.

Conclusions: Our results suggested the possible involvement of viral infections in breast carcinogenesis and adverse clinical outcomes by downregulating miR-143/145.

Keywords: *Papillomaviridae*, Human Herpesvirus, Human MicroRNA-143, Human MicroRNA-145, Breast Neoplasms

1. Background

Breast cancer is the most common malignancy in females worldwide. Only in the United States, 279,100 new cancer cases and 42,690 related deaths were projected to occur in 2020 (1). Breast cancer can begin in different parts of the breast, but most of them start from milk ducts and are called ductal carcinoma, which is the most common type of breast cancer. Lobular carcinomas are the second most frequent histologic forms of this malignancy, which begin in milk-producing lobules (2, 3). Less-common types of breast cancer include tubular, mucinous, comedo, and

medullary types (3). Tumor grades of I, II, and III are used to describe the rate of growth and spread of breast cancer cells (4). Breast cancer is a multifactorial event, and the role of viral infections in its etiology is largely proposed (5).

Approximately 12% of all human malignancies have a viral origin. Among them, DNA oncoviruses, including human papillomavirus (HPV) and Epstein-Barr virus (EBV), account for a notable proportion and impose a high disease burden that is becoming greater in the world (6, 7). Human papillomavirus, a member of the *Papillomaviridae* family, is a major etiological cause of cervical cancer. It possesses more than 150 genotypes, several types of them are

more implied to elevate the tumorigenesis risk (High-Risk HPV; HR-HPV) (8). Epstein-Barr virus, a member of the Herpesviridae family, was discovered as the first human oncovirus detected in Burkitt lymphoma cells in 1964 (6). The involvement of EBV is well-documented in a variety of human cancers, including Burkitt's lymphoma, nasopharyngeal carcinoma, Hodgkin's disease, and T cell lymphomas (6). Human papillomavirus and EBV infection can cooperatively participate in the pathogenesis of certain types of malignancies, such as breast carcinoma, due to their potential oncogenic effects on cells with an epithelial origin. Both HPV and EBV DNA oncoviruses are etiologically correlated with breast carcinoma development (9). Human papillomavirus and EBV DNA oncoviruses play a pivotal role in the pathogenesis of breast cancer. Accumulating evidence points out that these oncoviruses can co-exist in cancerous tissues of the breast and subsequently facilitate the initiation and progression of malignancies (10-12).

These viruses are capable of disrupting the diverse cellular machineries in the host. Inducing the inactivation of host tumor suppressor genes is a broad strategy that is exploited by oncoviruses in the development of cancers (13). One of the most important classes of these genes' inactivation is related to tumor suppressor microRNAs (miRNAs). As known, miRNAs include a category of endogenous non-coding RNAs with ~ 20 - 25 nucleotides in length and the ability to regulate gene expression via base-pairing at 3' UTRs (14). Based on specific tumor contexts and target base-pairing genes, miRNAs can act as tumor suppressors or oncogenes (15).

As a cluster of miRNAs, miR-143 and miR-145 are generated by two distinct co-transcribed miRNAs whose functions as tumor suppressors are intensively described (16). The suppressive effect of the miR-143/145 cluster on inhibiting the formation of epithelial tumors like breast cancer is clearly shown (17). In breast cancer cells, miR-143 and miR-145 synergistically repress cell proliferation and invasion; thereby, their downregulation arises malignancy-related hallmarks (18). Notably, the disruption of the miR-143/145 cluster has been observed in cancers associated with HPV and EBV human oncoviruses (19, 20).

Some infectious agents are well-described causes of chronic inflammation, which can derive carcinogenesis. Both HPV and EBV can establish persistent infection stimulating prolonged inflammation (21). These oncogenic viruses can upregulate various pro-inflammatory cytokines including IL-8 (22, 23). As a well-described pro-inflammatory cytokine, IL-8 is involved in breast tumors and with significant changes in serum level in these patients. Besides, IL-8 has a paracrine and/or autocrine tumor-promoting role in the manipulation of proliferation and survival of tumor cells (24). An elevated level of

IL-8 motivates the expression of angiogenic growth factors and cell adhesion molecules, leading to angiogenesis and metastasis in breast cancer patients (24, 25). As known, CXCR-1 and CXCR-2 are the leading receptors of IL-8, which are expressed in all breast cancer cells, representing the promoted sensitivity of cancer cells to IL-8 compared to normal breast cells (26). Importantly, functional analysis systems have revealed the implication of tumor suppressor miRNAs such as miR-145 in the secretion level of pro-inflammatory IL-8 (27).

2. Objectives

We newly sought the possible effect of viral infections on IL-8 by targeting tumor suppressor miR-143 and miR-145 in the serum of breast cancer patients. This is a particular part of virus-induced breast carcinogenesis that has not been considered yet. Here, we investigated the correlation between the viral presence and expression level of tumor suppressor miR-143 and miR-145 and clinical outcomes and their further effects on serum IL-8 in breast cancer patients.

3. Methods

3.1. Study Population and Collection of Specimens

A total of 70 tissue samples (35 cancerous tissues and 35 adjacent non-cancerous tissues) were used in the investigation collected from 35 women who had been diagnosed with breast carcinoma and had not undergone previous chemotherapy. Specimens were obtained from the primary tumors of subjects who underwent biopsies at different hospitals in Ahvaz province, Iran, from April 2020 to October 2020. The new cases with confirmed pathological evidence were included, and the patients who had a cancer history or metastatic cancer or received neoadjuvant chemotherapy were excluded.

In all women diagnosed with breast cancer, a breast examination was performed by an experienced surgeon. In addition, tissue samples were evaluated for the histopathologic assessment of breast cancer according to the WHO criteria by two experienced pathologists to ensure the correct diagnosis. All tissue specimens were immediately frozen in liquid nitrogen after biopsy and stored at -80°C for subsequent research. Also, all patients signed an informed consent form concerning the participation in the study. Before the needle biopsy, for all the enrolled women (n = 35), serum samples were collected and stored at -80°C until analysis. We also collected 35 serum samples from healthy normal individuals/volunteers (without a history of malignancy and chronic inflammatory diseases) as a serum control group to determine the difference in cytokine levels between patients and normal subjects.

3.2. Genomic DNA Preparation, Polymerase Chain Reaction, and Genotyping

The DNA extraction was carried out using QIAamp DNA Mini Kit (Cat No./ID: 51304) based on the manufacturer's protocols. The amplification of the human β -globin gene was performed using PCO3/PCO4 primers (Table 1) to evaluate the quality of the extracted material, and positive samples underwent further investigations. Specimens were screened for the presence of HPV utilizing the nested PCR method with primers specific to the L1 region of the HPV genome (Table 1). For both rounds, PCR conditions included 1X PCR buffer, 300 - 400 ng of template DNA, 1 mM MgCl₂, 100 mM deoxynucleotide triphosphates (dNTPs), 10 pmol of each primer, and 0.5 U of Taq polymerase in a total volume of 25 μ L. The first-round PCR thermal profile was 95°C for 7 min, followed by 40 cycles of 94°C for 45 s, 50°C for 45 s, 72°C for 45 s, and a final extension for 7 min at 72°C. The second round started with 95°C for 5 min, followed by 40 cycles of 94°C for 30 s, 50°C for 30 s, 72°C for 30 s, and a final extension for 7 min at 72°C.

For EBV detection, the EBNA-1 coding region was amplified (bp) by nested PCR, using specific primers (Table 1). Each PCR was performed in 25 μ L of a reaction mixture containing 25 pmol of each of outer and inner primers, 100 μ M dNTPs, 1X PCR buffer, 1.5 mM MgCl₂, one unit of Taq polymerase enzyme (Amplicon, USA), and 300 ng of extracted/product DNA. The PCR cycling protocol included 10 min at 94°C, followed by 45 s at 94°C, 45 s at 53°C, and one minute at 72°C for 35 cycles in the first PCR, and 5 min at 94°C, 45 s at 94°C, 45s at 63°C, and one minute at 72°C for 35 cycles in the second PCR. In the next step, PCR products were excised from an agarose gel (Figures 1-3) and purified. Subsequently, they underwent direct sequencing using ABI PRISM 3100 (Applied Biosystems) to confirm the viral presence and determine the HPV genotype.




Figure 1. Positive polymerase chain reaction bands corresponding β -globin




Figure 2. Positive polymerase chain reaction bands corresponding HPV-L1. Sample 1, negative control; Samples 2 to 5, 7, 8, patient samples; Sample 9, positive control; Sample 10, 50 bp ladder.




Figure 3. Positive polymerase chain reaction bands corresponding EBV-EBNA1. Samples 1 to 7, patient samples; Sample 8, positive control; Sample 9, negative control; Sample 10, 100 bp ladder.

3.3. RNA Isolation and Reverse Transcription-Quantitative Polymerase Chain Reaction (RT-qPCR)

In this study, miRNAs were extracted from cancerous tissues and the matched normal tissue specimens, using the RNA Minipreps Kit (Bio Basic, Inc.) according to the kit instruction. The concentration and purity of RNA were measured with NanoDrop™ via N-D 2000 (Thermo Scientific, USA). In this step, 1 μ g of extracted RNA template was reverse-transcribed to cDNA in a final volume of 20 μ L, employing the BON-Stem miR cDNA synthesis (Cat No. BN-0011.17.2, Iran) based on the manufacturer's protocol. To evaluate the gene expression of the miR-143/145 cluster, RT-qPCR was carried out with the BON-miR qPCR Kit (Cat No. BON209002, Iran) in a StepOnePlus Real-Time PCR System (Applied Biosystems, Foster City, USA). The PCR reaction mixture was in a final volume of 13 μ L containing 1 μ L of

Table 1. Sequences and Other Characteristics of Primers Used in This Study

Locus	Oligonucleotide Sequence	ORF	Fragment Size	Reference
<i>β</i>-globin		<i>β</i> -globin	110	(28)
PCO3	ACACAACCTGTGTTCACTAGC			
PCO4	CAACTTCATCCACGTTCCACC			
EBV		EBNA1	609	(29)
F1	GTAGAAGGCCATTTTCCAC			
R1	CTCCATCGTCAAAGCTGCA			
EBV		EBNA1	308	-
F2	AGATGACCCAGGAGAAGGCCAAGC			
R2	CAAAGGGGAGACGACTCAATGGTGT			
HPV		L1	450	(30)
F1	CGTCCMARRGGAWACTGATC			
R1	GCMCAGGGWCATAAYAATGG			
HPV		L1	150	-
F2	TTTGTACTGTGGTAGATACTAC			
R2	GAAAAATAAAGCTAAATCATATTC			

cDNA, 0.5 mM of each primer, and 2 × miRNA QPCR master mix Passive reference dye I (ROX) (Cat No. BN-0011.17.3, Iran). The amplification conditions were 5 min at 95°C, 40 cycles of 5 s at 95°C, and 30 s at 58°C, followed by a melting curve cycle. The reactions were normalized to the expression of endogenous control SNORD47. Each test was performed in duplicate. The $2^{-\Delta\Delta Ct}$ formula was used to determine the expression levels of miR-143 and miR-145.

3.4. Cytokine Assessment

All sera taken from patients (n = 35) and normal controls (n = 35) underwent testing for circulating IL-8 levels by the Human IL-8 ELISA® Kit (Karmania Pars Gene, Iran), based on the manufacturer's instructions with a sensitivity of 3.0 pg/mL. The IL-8 level of each serum specimen was examined two times and an average was reported.

3.5. Statistical Analysis

The normality of data was tested using the Kolmogorov-Smirnov test for continuous variables. The Mann-Whitney U test was used to assess the differences in miR-143, miR-145, and cytokine levels between patients and controls. The chi-square test was used to assess the association of the groups with viruses, as well as with clinicopathological factors of patients. All data were evaluated using the Statistical Package for the Social Sciences (SPSS), version 22 (IBM), and Graphpad Prism, version 8.0.2 (Graphpad Software, Inc.). The P-values < 0.05 (*), < 0.01 (**), < 0.001(***), and < 0.0001(****) were considered statistically significant.

4. Results

4.1. Clinical Parameters and Screening for Virus Presence

A total of 70 fresh frozen breast carcinoma tissue biopsies from 35 patients were included in this research. The patients' age ranged from 24 to 68 years in the cancerous group (mean 47.4 ± 12.7 y) and 27 to 64 in healthy individuals (mean 45.3 ± 14.7 y). The clinical data and presence of viral infection are summarized in Table 2. The screening of the viral genome for HPV and EBV showed that 14.2% (10/70) and 7% (5/70) were positive, respectively (Figures 2 and 3, Table 3). The detection of HPV DNA was significantly different between cancerous tissues (cases) and adjacent non-cancerous tissues (controls), while no significant difference was observed for EBV DNA (Table 3). Although two samples possessed a co-infection of HPV and EBV, its correlation with the case and control groups was not significant (Table 3). Human papillomavirus genotyping indicated HPV 16 (n = 5), HPV 73 (n = 2), HPV 53 (n = 1), and HPV 31 (n = 1) in the case group and HPV 16 (n = 1) in the control group.

4.2. Gene Expression of miR-143/145 Cluster

The expression levels of miR-143 and miR-145 were determined via RT-qPCR in cancerous and adjacent non-cancerous tissues of breast cancer patients. The relative expression of miR-143 and miR-145 was normalized by SNORD47. In comparison with adjacent non-cancerous tissues, the expression levels of both miR-143 and miR-145

Table 2. Clinical Parameters and Presence of Viral Infection

Parameter	Total, n = 35	HPV+, n = 10	HPV-, n = 25	EBV+, n = 5	EBV-, n = 30	HPV/EBV, n = 2
Age (y)	47.4 ± 12.7	51.1 ± 13.3	46.8 ± 12.5	55 ± 10.2	46.8 ± 12.6	48.5 ± 13.4
Type of cancer						
Ductal	31 (88.5)	7 (22.5)	24 (77.4)	4 (12.9)	27 (87)	2 (6.4)
Lobular	2 (5.7)	1 (50)	1 (50)	0	2 (100)	0
Medullary	1 (2.9)	1 (100)	0	0	1 (100)	0
Tubular	1 (2.9)	0	1 (100)	0	1 (100)	0
Grade						
I	15 (42.9)	2 (13.3)	13 (86.6)	2 (13.3)	13 (86.6)	0
II	8 (22.9)	3 (37.5)	5 (62.5)	1 (12.5)	7 (87.5)	1 (12.5)
III	12 (34.3)	4 (33.3)	8 (66.6)	1 (8.3)	11 (91.6)	1 (8.3)
Metastasis	6 (100)	5 (83.3) **	1 (16.6)	1 (16.6)	5 (83.3)	1 (16.6)

^a Values are expressed as No. (%) unless otherwise expressed.

^b The P-value < 0.01 (**) were considered statistically significant.

Table 3. Viral Presence in Case and Control Groups ^{a, b}

Normal/Tumor Tissue	HPV and EBV Detection		
	HPV	EBV	HPV/EBV Co-infection
Normal	1 (2.9)	1 (2.9)	0
Tumor	9 (25.7)	4 (11.4)	2 (5.8)
P-Value	0.006 **	0.164	0.151

^a Values are expressed as No. (%) unless otherwise expressed.

^b The P-value < 0.01 (**) were considered statistically significant.

were reduced in the breast cancer group, and the difference was statistically significant ($P < 0.0001$). The results of miR-143/145 expression in the tumor and normal groups are shown in Figure 4. The analysis showed a direct association between HPV and EBV positivity and a reduced expression level of miR-143 and miR-145 (Figure 5). In addition, there was a correlation between the reduced expression of the miR-143/145 cluster and metastasis according to HPV positivity ($P = 0.003$).

4.3. Serum Interleukin-8

Interleukin-8 concentrations were determined by enzyme-linked immunosorbent assays (ELISA) in serum specimens. Serum concentrations of IL-8 were almost similar between patients and controls ($P = 0.296$) (Table 4). We found no statistically significant correlation between patients who were infected with HPV/EBV and non-infected patients according to the concentration of IL-8 in serum (Table 4). Additionally, no correlation was found between the IL-8 serum level and clinicopathological data.

5. Discussion

Human papillomavirus and EBV DNA oncoviruses account for nearly two-thirds of all virus-associated malignancies (31). Human papillomavirus and EBV can co-exist and cooperate in human cancers, especially breast cancer (32). The prevalence of HPV in breast cancer varies widely from 1.6 to 86.2% among countries around the world (33). This rate in Iran has been reported in various studies from 6.7 to 40.5%, which is considered to be 23.7% on average (34). However, the prevalence of EBV in different countries of the world among women with breast cancer is reported from 0 to 78.1%, and 26.3% on average. It has the highest prevalence in Europe and the lowest in North America. In various studies in Iran, different prevalence rates have been reported from 0 to 35.3% (35).

Carcinogenic properties of these DNA oncoviruses allow them to drive cell transformation and tumor development. Alterations in host cell miRNA expression can be done by HPV and EBV as a pivotal mechanism involved in virus-mediated oncogenesis (36). The current research was undertaken to investigate the correlation between the presence of oncoviruses, HPV and EBV, and probable dys-




Figure 4. Comparison of miR-143/145 expression levels based on normal or cancerous tissue




Figure 5. Comparison of miR-143/145 expression levels based on the presence or absence of viruses

Table 4. Serum IL-8 Concentrations Based on Case and Control Groups and Presence of Viral Infection

Group	Mean ± SD	P-Value
Control	15.4 ± 7.6	0.14
Case	18.7 ± 12.2	
HPV+	24.2 ± 21.1	0.788
HPV-	16.5 ± 5.2	
EBV+	22.5 ± 18.6	0.766
EBV-	18.1 ± 11.2	

regulation of tumor suppressor miRNAs, miR-143 and miR-145, in breast cancer patients and evaluate their potential link to the clinical outcome. In the first step, we explored the prevalence of HPV and EBV in breast cancer tissue and corresponding adjacent non-cancerous tissues using nested-PCR. Human papillomavirus was significantly different between the case and control groups (Table 3).

There is a range of discrepancies in the literature concerning the HPV prevalence in breast cancer patients. In line with our data, investigations involving cases and controls indicate a higher frequency of HPV in tumor tissues (37-41), while there are some studies that reported contradictory data (42, 43). The distribution of the HPV genotype in this research indicated that all detected types belonged to high-risk HPV. Human papillomavirus 16 was the most abundant type present in the patients. This HPV type has been frequently detected as the most prevalent type in other studies of breast cancer (39, 44).

For EBV, the screening of the viral genome did not show any correlation with the case and control groups ($P = 0.164$) (Table 3). The rate of EBV infection in breast cancer patients was not unexpected, as the virus has been detected in many studies to be absent or be at a low rate at this site (45-47). However, we did not observe any significant association between breast cancer and EBV presence. The more frequency rate of EBV and HPV in cancerous tissue may represent the increasing role of EBV in the development of breast cancer. For instance, an investigation conducted by Makielski et al. in oral cancer (48) proposed that infection with HPV may raise the capacity of epithelial cells to assist the EBV life cycle that could, in turn, elevate EBV-related pathogenesis in malignancy. In this regard, another study demonstrated that HPV/EBV coinfection enhanced EBV persistency via either latency or increased virus replication, as well as by elevating HPV oncogene expression (49). Therefore, EBV co-presence with HPV infection, even at low levels, might affect the susceptibility of breast epithelial cells to carcinogenesis.

Our data further indicated that less expression of these miRNAs was associated with a positive status of HPV in patients (Figure 5). Our results are consistent with data in the literature, indicating that miR-143 and miR-145 are largely dysregulated in HPV-associated cancers. Wang et al. demonstrated that the downregulation of miR-143/145 is a key factor for tumor growth in HPV-related cervical carcinogenesis (19). Baffa et al. also mentioned a reduced expression of miR-143/145 in HPV-related head and neck cancers (50). Reports imply the role of viral oncoproteins as a cause of suppressing the miRNAs. For example, it has been observed that the inhibition of HPV oncoproteins (E6 and E7) expression may trigger miR-143 upregulation in infected cells (51).

Intriguingly, we also realized a correlation between the reduced expression of the miR-143/145 cluster and metastasis according to HPV positivity ($P = 0.003$). The available data point out the capacity of HPV for triggering metastasis and inducing more aggressive phenotypes in breast carcinoma (31). Furthermore, the evidence demonstrated that miR-143/145 expression was negatively related to lymph node metastasis, and patients with lower levels of miR-143/145 expression may be subject to poor prognosis malignancies (52, 53). Collectively, our findings may present a novel mechanism by which HPV provokes breast cancer metastasis.

Therefore, considering the confirmed relationship between HPV and decreased miR-143/145 expressions in various malignancies and due to the close association between miR-143/145 downregulation and breast cancer, the findings of the current study may suggest the participation of HPV in the pathogenesis of breast carcinoma and adverse clinical outcomes such as the promotion of metastasis. Further analysis also showed less expression of miR-143/145 in the EBV-positive group as compared to the EBV-negative group (Figure 5). Very few reports have highlighted the correlation between EBV infection and the expression status of miR-143/145 (54). A study conducted in 2015 by Bazot et al. showed EBV capacity in silencing the expression of the miR-143/145 cluster in infected cells (20). They proposed EBV EBNA3A and EBNA3C protein implications in this process. Although herein, a significant result was gained in this respect, further studies seem to be needed to precisely evaluate the impact of EBV on these tumor suppressor miRNAs in breast carcinoma development.

In the final step, we speculated whether viral infection, especially HPV, can affect IL-8 production systematically via the disruption of two tumor suppressor miRNAs (miR-143 and miR-145). The elevation in the IL-8 serum level is suggested to be related to the development and progression of breast carcinogenesis (24). For this purpose, we obtained serum specimens from all patients in the current investigation and healthy controls. The comparative analysis based on the IL-8 serum concentration within different groups (Table 4) did not show any significant difference. Although some data have shown the promotion of serum levels of IL-8 upon viral persistent infections such as HPV and EBV (55, 56), studies remark the differences in the biology of viral infections in different types of cancers and the sensitivity of testing methods.

5.1. Conclusions

Our study may present strong data for the engagement of DNA oncoviruses, including HPV and EBV, in the promotion of breast carcinoma and metastasis via downregulating miR-143/145. Collectively, the results may suggest the

use of viral vaccination for prevention or prescription of antiviral regimes in combination with other breast cancer therapies for infected people and application of miR-143/145 as a useful predictive biomarker for breast cancer outcome. However, further studies seem to be necessary.

Acknowledgments

This study was performed as part of a Ph.D. thesis by Mohsen Nakhaie, and was supported financially by Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran, by grant number CRC-9905. We, also thank individuals and organizations who participated in this research.

Footnotes

Authors' Contribution: Study concept and design, Manoochehr Makvandi, Mohsen Nakhaie, and Gholam Abbas Kaydani; Analysis and interpretation of data, Mohsen Nakhaie, Javad Charostad, and Azim Motamedfar; Drafting of the manuscript, Javad Charostad; Critical revision of the manuscript for important intellectual content, Seyyed Ali Mohammad Arabzadeh; Statistical analysis, Mohsen Nakhaie.

Conflict of Interests: All authors declared that they have no conflict of interest.

Ethical Approval: The project received approval from the Ethics Committee of Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran, under number IR.AJUMS.REC.1399.091.

Funding/Support: This study was financially supported by Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran, by grant number CRC-9905.

Informed Consent: All patients signed the informed consent form before participation.

References

- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. *CA Cancer J Clin*. 2020;**70**(1):7-30. doi: [10.3322/caac.21590](https://doi.org/10.3322/caac.21590). [PubMed: [31912902](https://pubmed.ncbi.nlm.nih.gov/31912902/)].
- Sharma GN, Dave R, Sanadya J, Sharma P, Sharma KK. Various types and management of breast cancer: An overview. *J Adv Pharm Technol Res*. 2010;**1**(2):109-26. [PubMed: [22247839](https://pubmed.ncbi.nlm.nih.gov/22247839/)]. [PubMed Central: [PMC3255438](https://pubmed.ncbi.nlm.nih.gov/PMC3255438/)].
- Li CI, Uribe DJ, Daling JR. Clinical characteristics of different histologic types of breast cancer. *Br J Cancer*. 2005;**93**(9):1046-52. doi: [10.1038/sj.bjc.6602787](https://doi.org/10.1038/sj.bjc.6602787). [PubMed: [16175185](https://pubmed.ncbi.nlm.nih.gov/16175185/)]. [PubMed Central: [PMC2361680](https://pubmed.ncbi.nlm.nih.gov/PMC2361680/)].
- Rakha EA, Reis-Filho JS, Baehner F, Dabbs DJ, Decker T, Eusebi V, et al. Breast cancer prognostic classification in the molecular era: The role of histological grade. *Breast Cancer Res*. 2010;**12**(4):207. doi: [10.1186/bcr2607](https://doi.org/10.1186/bcr2607). [PubMed: [20804570](https://pubmed.ncbi.nlm.nih.gov/20804570/)]. [PubMed Central: [PMC2949637](https://pubmed.ncbi.nlm.nih.gov/PMC2949637/)].
- Gannon OM, Antonsson A, Bennett IC, Saunders NA. Viral infections and breast cancer - A current perspective. *Cancer Lett*. 2018;**420**:182-9. doi: [10.1016/j.canlet.2018.01.076](https://doi.org/10.1016/j.canlet.2018.01.076). [PubMed: [29410005](https://pubmed.ncbi.nlm.nih.gov/29410005/)].
- Mui UN, Haley CT, Tyring SK. Viral oncology: Molecular biology and pathogenesis. *J Clin Med*. 2017;**6**(12). doi: [10.3390/jcm6120111](https://doi.org/10.3390/jcm6120111). [PubMed: [29186062](https://pubmed.ncbi.nlm.nih.gov/29186062/)]. [PubMed Central: [PMC5742800](https://pubmed.ncbi.nlm.nih.gov/PMC5742800/)].
- Alizon S, Bravo IG, Farrell PJ, Roberts S. Towards a multi-level and a multi-disciplinary approach to DNA oncovirus virulence. *Philos Trans R Soc Lond B Biol Sci*. 2019;**374**(1773):20190041. doi: [10.1098/rstb.2019.0041](https://doi.org/10.1098/rstb.2019.0041). [PubMed: [30955496](https://pubmed.ncbi.nlm.nih.gov/30955496/)]. [PubMed Central: [PMC6501900](https://pubmed.ncbi.nlm.nih.gov/PMC6501900/)].
- Kovachev SM, Slavov VD. Causative relations between human papilloma virus infection and cervical intraepithelial neoplasia. *Biotechnol Biotechnol Equip*. 2016;**30**(3):558-61. doi: [10.1080/13102818.2016.1159922](https://doi.org/10.1080/13102818.2016.1159922).
- Lawson JS, Salmons B, Glenn WK. Oncogenic viruses and breast cancer: Mouse mammary tumor virus (MMTV), bovine leukemia virus (BLV), human papilloma virus (HPV), and Epstein-Barr virus (EBV). *Front Oncol*. 2018;**8**:1. doi: [10.3389/fonc.2018.00001](https://doi.org/10.3389/fonc.2018.00001). [PubMed: [29404275](https://pubmed.ncbi.nlm.nih.gov/29404275/)]. [PubMed Central: [PMC5786831](https://pubmed.ncbi.nlm.nih.gov/PMC5786831/)].
- Glenn WK, Heng B, Delprado W, Iacopetta B, Whitaker NJ, Lawson JS. Epstein-Barr virus, human papillomavirus and mouse mammary tumour virus as multiple viruses in breast cancer. *PLoS One*. 2012;**7**(11). e48788. doi: [10.1371/journal.pone.0048788](https://doi.org/10.1371/journal.pone.0048788). [PubMed: [23183846](https://pubmed.ncbi.nlm.nih.gov/23183846/)]. [PubMed Central: [PMC3501510](https://pubmed.ncbi.nlm.nih.gov/PMC3501510/)].
- Naushad W, Surriya O, Sadia H. Prevalence of EBV, HPV and MMTV in Pakistani breast cancer patients: A possible etiological role of viruses in breast cancer. *Infect Genet Evol*. 2017;**54**:230-7. doi: [10.1016/j.meegid.2017.07.010](https://doi.org/10.1016/j.meegid.2017.07.010). [PubMed: [28705719](https://pubmed.ncbi.nlm.nih.gov/28705719/)].
- Aguayo F, Khan N, Koriyama C, Gonzalez C, Ampuero S, Padilla O, et al. Human papillomavirus and Epstein-Barr virus infections in breast cancer from Chile. *Infect Agent Cancer*. 2011;**6**(1):7. doi: [10.1186/1750-9378-6-7](https://doi.org/10.1186/1750-9378-6-7). [PubMed: [21699721](https://pubmed.ncbi.nlm.nih.gov/21699721/)]. [PubMed Central: [PMC3141534](https://pubmed.ncbi.nlm.nih.gov/PMC3141534/)].
- Guyen-Maiorov E, Tsai CJ, Nussinov R. Oncoviruses can drive cancer by rewiring signaling pathways through interface mimicry. *Front Oncol*. 2019;**9**:1236. doi: [10.3389/fonc.2019.01236](https://doi.org/10.3389/fonc.2019.01236). [PubMed: [31803618](https://pubmed.ncbi.nlm.nih.gov/31803618/)]. [PubMed Central: [PMC6872517](https://pubmed.ncbi.nlm.nih.gov/PMC6872517/)].
- Zhang B, Pan X, Cobb GP, Anderson TA. MicroRNAs as oncogenes and tumor suppressors. *Dev Biol*. 2007;**302**(1):1-12. doi: [10.1016/j.ydbio.2006.08.028](https://doi.org/10.1016/j.ydbio.2006.08.028). [PubMed: [16989803](https://pubmed.ncbi.nlm.nih.gov/16989803/)].
- Li J, Zhang Z, Chen F, Hu T, Peng W, Gu Q, et al. The diverse oncogenic and tumor suppressor roles of microRNA-105 in cancer. *Front Oncol*. 2019;**9**:518. doi: [10.3389/fonc.2019.00518](https://doi.org/10.3389/fonc.2019.00518). [PubMed: [31281797](https://pubmed.ncbi.nlm.nih.gov/31281797/)]. [PubMed Central: [PMC6595394](https://pubmed.ncbi.nlm.nih.gov/PMC6595394/)].
- Almeida MI, Calin GA. The miR-143/miR-145 cluster and the tumor microenvironment: Unexpected roles. *Genome Med*. 2016;**8**(1):29. doi: [10.1186/s13073-016-0284-1](https://doi.org/10.1186/s13073-016-0284-1). [PubMed: [26988859](https://pubmed.ncbi.nlm.nih.gov/26988859/)]. [PubMed Central: [PMC4797185](https://pubmed.ncbi.nlm.nih.gov/PMC4797185/)].
- Das AV, Pillai RM. Implications of miR cluster 143/145 as universal anti-oncomiRs and their dysregulation during tumorigenesis. *Cancer Cell Int*. 2015;**15**:92. doi: [10.1186/s12935-015-0247-4](https://doi.org/10.1186/s12935-015-0247-4). [PubMed: [26425114](https://pubmed.ncbi.nlm.nih.gov/26425114/)]. [PubMed Central: [PMC4588501](https://pubmed.ncbi.nlm.nih.gov/PMC4588501/)].
- Yan X, Chen X, Liang H, Deng T, Chen W, Zhang S, et al. miR-143 and miR-145 synergistically regulate ERBB3 to suppress cell proliferation and invasion in breast cancer. *Mol Cancer*. 2014;**13**:220. doi: [10.1186/1476-4598-13-220](https://doi.org/10.1186/1476-4598-13-220). [PubMed: [25248370](https://pubmed.ncbi.nlm.nih.gov/25248370/)]. [PubMed Central: [PMC4181414](https://pubmed.ncbi.nlm.nih.gov/PMC4181414/)].
- Wang X, Tang S, Le SY, Lu R, Rader JS, Meyers C, et al. Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. *PLoS One*. 2008;**3**(7). e2557. doi: [10.1371/journal.pone.0002557](https://doi.org/10.1371/journal.pone.0002557). [PubMed: [18596939](https://pubmed.ncbi.nlm.nih.gov/18596939/)]. [PubMed Central: [PMC2438475](https://pubmed.ncbi.nlm.nih.gov/PMC2438475/)].
- Bazot Q, Paschos K, Skalska L, Kalchschmidt JS, Parker GA, Allday MJ. Epstein-Barr virus proteins EBNA3A and EBNA3C together induce expression of the oncogenic microRNA cluster miR-221/miR-222 and ablate expression of its target p57KIP2. *PLoS Pathog*. 2015;**11**(7). e1005031. doi: [10.1371/journal.ppat.1005031](https://doi.org/10.1371/journal.ppat.1005031). [PubMed: [26153983](https://pubmed.ncbi.nlm.nih.gov/26153983/)]. [PubMed Central: [PMC4496050](https://pubmed.ncbi.nlm.nih.gov/PMC4496050/)].

21. Read SA, Douglas MW. Virus induced inflammation and cancer development. *Cancer Lett.* 2014;**345**(2):174–81. doi: [10.1016/j.canlet.2013.07.030](https://doi.org/10.1016/j.canlet.2013.07.030). [PubMed: [23941825](https://pubmed.ncbi.nlm.nih.gov/23941825/)].
22. Shiau MY, Fan LC, Yang SC, Tsao CH, Lee H, Cheng YW, et al. Human papillomavirus up-regulates MMP-2 and MMP-9 expression and activity by inducing interleukin-8 in lung adenocarcinomas. *PLoS One.* 2013;**8**(1): e54423. doi: [10.1371/journal.pone.0054423](https://doi.org/10.1371/journal.pone.0054423). [PubMed: [23349885](https://pubmed.ncbi.nlm.nih.gov/23349885/)]. [PubMed Central: [PMC3549962](https://pubmed.ncbi.nlm.nih.gov/PMC3549962/)].
23. Fernandes JV, Fernandes TAdM, De Azevedo JCV, Cobucci RNO, De Carvalho MGF, Andrade VS, et al. Link between chronic inflammation and human papillomavirus-induced carcinogenesis (Review). *Oncol Lett.* 2015;**9**(3):1015–26. doi: [10.3892/ol.2015.2884](https://doi.org/10.3892/ol.2015.2884). [PubMed: [25663851](https://pubmed.ncbi.nlm.nih.gov/25663851/)]. [PubMed Central: [PMC4315066](https://pubmed.ncbi.nlm.nih.gov/PMC4315066/)].
24. Todorovic-Rakovic N, Milovanovic J. Interleukin-8 in breast cancer progression. *J Interferon Cytokine Res.* 2013;**33**(10):563–70. doi: [10.1089/jir.2013.0023](https://doi.org/10.1089/jir.2013.0023). [PubMed: [23697558](https://pubmed.ncbi.nlm.nih.gov/23697558/)]. [PubMed Central: [PMC3793647](https://pubmed.ncbi.nlm.nih.gov/PMC3793647/)].
25. Sheikhpour R. The role of interleukin-8 and its mechanism in patients with breast cancer: Its relation with oxidative stress and estrogen receptor. *Int J Cancer Manag.* 2017;**10**(9). doi: [10.5812/ijcm.8791](https://doi.org/10.5812/ijcm.8791).
26. Miller LJ, Kurtzman SH, Wang Y, Anderson KH, Lindquist RR, Kreutzer DL. Expression of interleukin-8 receptors on tumor cells and vascular endothelial cells in human breast cancer tissue. *Anticancer Res.* 1998;**18**(1A):77–81. [PubMed: [9568059](https://pubmed.ncbi.nlm.nih.gov/9568059/)].
27. Dang X, Yang L, Guo J, Hu H, Li F, Liu Y, et al. miR-145-5p is associated with smoke-related chronic obstructive pulmonary disease via targeting KLF5. *Chem Biol Interact.* 2019;**300**:82–90. doi: [10.1016/j.cbi.2019.01.011](https://doi.org/10.1016/j.cbi.2019.01.011). [PubMed: [30639269](https://pubmed.ncbi.nlm.nih.gov/30639269/)].
28. Caballero OL, Menezes CL, Costa MC, Fernandes SC, Anacleto TM, de Oliveira RM, et al. Highly sensitive single-step PCR protocol for diagnosis and monitoring of human cytomegalovirus infection in renal transplant recipients. *J Clin Microbiol.* 1997;**35**(12):3192–7. doi: [10.1128/JCM.35.12.3192-3197.1997](https://doi.org/10.1128/JCM.35.12.3192-3197.1997). [PubMed: [9399518](https://pubmed.ncbi.nlm.nih.gov/9399518/)]. [PubMed Central: [PMC230146](https://pubmed.ncbi.nlm.nih.gov/PMC230146/)].
29. Homayouni M, Mohammad Arabzadeh SA, Nili F, Razi F, Amoli MM. Evaluation of the presence of Epstein-Barr virus (EBV) in Iranian patients with thyroid papillary carcinoma. *Pathol Res Pract.* 2017;**213**(7):854–6. doi: [10.1016/j.prp.2017.01.020](https://doi.org/10.1016/j.prp.2017.01.020). [PubMed: [28554750](https://pubmed.ncbi.nlm.nih.gov/28554750/)].
30. Taherian H, Tafvizi F, Fard ZT, Abdirad A. Lack of association between human papillomavirus infection and colorectal cancer. *Prz Gastroenterol.* 2014;**9**(5):280–4. doi: [10.5114/pg.2014.46163](https://doi.org/10.5114/pg.2014.46163). [PubMed: [25396002](https://pubmed.ncbi.nlm.nih.gov/25396002/)]. [PubMed Central: [PMC4223116](https://pubmed.ncbi.nlm.nih.gov/PMC4223116/)].
31. Cyprian FS, Al-Farsi HF, Vranic S, Akhtar S, Al Moustafa AE. Epstein-Barr virus and human papillomaviruses interactions and their roles in the initiation of epithelial-mesenchymal transition and cancer progression. *Front Oncol.* 2018;**8**:111. doi: [10.3389/fonc.2018.00111](https://doi.org/10.3389/fonc.2018.00111). [PubMed: [29765906](https://pubmed.ncbi.nlm.nih.gov/29765906/)]. [PubMed Central: [PMC5938391](https://pubmed.ncbi.nlm.nih.gov/PMC5938391/)].
32. Al Moustafa A-E, Al-Antary N, Aboukassim T, Akil N, Batist G, Yasmeen A. Co-prevalence of Epstein-Barr virus and high-risk human papillomaviruses in syrian women with breast cancer. *Hum Vaccin Immunother.* 2016;**12**(7):1936–9. doi: [10.1080/21645515.2016.1139255](https://doi.org/10.1080/21645515.2016.1139255). [PubMed: [27082145](https://pubmed.ncbi.nlm.nih.gov/27082145/)]. [PubMed Central: [PMC4964818](https://pubmed.ncbi.nlm.nih.gov/PMC4964818/)].
33. Islam MS, Chakraborty B, Panda CK. Human papilloma virus (HPV) profiles in breast cancer: future management. *Ann Transl Med.* 2020;**8**(10):650. doi: [10.21037/atm-19-2756](https://doi.org/10.21037/atm-19-2756). [PubMed: [32566587](https://pubmed.ncbi.nlm.nih.gov/32566587/)]. [PubMed Central: [PMC7290605](https://pubmed.ncbi.nlm.nih.gov/PMC7290605/)].
34. Haghshenas MR, Mousavi T, Moosazadeh M, Afshari M. Human papillomavirus and breast cancer in Iran: A meta-analysis. *Iran J Basic Med Sci.* 2016;**19**(3):231–7. [PubMed: [27114791](https://pubmed.ncbi.nlm.nih.gov/27114791/)]. [PubMed Central: [PMC4834111](https://pubmed.ncbi.nlm.nih.gov/PMC4834111/)].
35. Farahmand M, Monavari SH, Shoja Z, Ghaffari H, Tavakoli M, Tavakoli A. Epstein-Barr virus and risk of breast cancer: A systematic review and meta-analysis. *Future Oncol.* 2019;**15**(24):2873–85. doi: [10.2217/fon-2019-0232](https://doi.org/10.2217/fon-2019-0232). [PubMed: [31342783](https://pubmed.ncbi.nlm.nih.gov/31342783/)].
36. Vojtechova Z, Tachezy R. The role of miRNAs in virus-mediated oncogenesis. *Int J Mol Sci.* 2018;**19**(4). doi: [10.3390/ijms19041217](https://doi.org/10.3390/ijms19041217). [PubMed: [29673190](https://pubmed.ncbi.nlm.nih.gov/29673190/)]. [PubMed Central: [PMC5979478](https://pubmed.ncbi.nlm.nih.gov/PMC5979478/)].
37. Cavalcante JR, Pinheiro LG, Almeida PR, Ferreira MV, Cruz GA, Campelo TA, et al. Association of breast cancer with human papillomavirus (HPV) infection in Northeast Brazil: Molecular evidence. *Clinics.* 2018;**73**:e465. doi: [10.6061/clinics/2018/e465](https://doi.org/10.6061/clinics/2018/e465). [PubMed: [30365827](https://pubmed.ncbi.nlm.nih.gov/30365827/)]. [PubMed Central: [PMC6172977](https://pubmed.ncbi.nlm.nih.gov/PMC6172977/)].
38. Gumus M, Yumuk PF, Salepci T, Aliustaoglu M, Dane F, Ekenel M, et al. HPV DNA frequency and subset analysis in human breast cancer patients' normal and tumoral tissue samples. *J Exp Clin Cancer Res.* 2006;**25**(4):515–21. [PubMed: [17310842](https://pubmed.ncbi.nlm.nih.gov/17310842/)].
39. Khan NA, Castillo A, Koriyama C, Kijima Y, Umekita Y, Ohi Y, et al. Human papillomavirus detected in female breast carcinomas in Japan. *Br J Cancer.* 2008;**99**(3):408–14. doi: [10.1038/sj.bjc.6604502](https://doi.org/10.1038/sj.bjc.6604502). [PubMed: [18648364](https://pubmed.ncbi.nlm.nih.gov/18648364/)]. [PubMed Central: [PMC2527789](https://pubmed.ncbi.nlm.nih.gov/PMC2527789/)].
40. de Leon DC, Montiel DP, Nemcova J, Mykyskova I, Turcios E, Villavicencio V, et al. Human papillomavirus (HPV) in breast tumors: prevalence in a group of Mexican patients. *BMC Cancer.* 2009;**9**:26. doi: [10.1186/1471-2407-9-26](https://doi.org/10.1186/1471-2407-9-26). [PubMed: [19161629](https://pubmed.ncbi.nlm.nih.gov/19161629/)]. [PubMed Central: [PMC2636825](https://pubmed.ncbi.nlm.nih.gov/PMC2636825/)].
41. He Q, Zhang SQ, Chu YL, Jia XL, Wang XL. The correlations between HPV16 infection and expressions of c-erbB-2 and bcl-2 in breast carcinoma. *Mol Biol Rep.* 2009;**36**(4):807–12. doi: [10.1007/s11033-008-9249-9](https://doi.org/10.1007/s11033-008-9249-9). [PubMed: [18427947](https://pubmed.ncbi.nlm.nih.gov/18427947/)].
42. Eslamifar A, Ramezani A, Azadmanesh K, Bidari-Zerehpoo F, Banifazl M, Aghakhani A. Assessment of the association between human papillomavirus infection and breast carcinoma. *Iran J Pathol.* 2015;**10**(1):41–6. [PubMed: [26516324](https://pubmed.ncbi.nlm.nih.gov/26516324/)]. [PubMed Central: [PMC4539779](https://pubmed.ncbi.nlm.nih.gov/PMC4539779/)].
43. Kwong A, Leung CP, Shin VY, Ng EK. No evidence of human papillomavirus in patients with breast cancer in Hong Kong, Southern China. *ISRN Virology.* 2013;**2013**:1–4. doi: [10.5402/2013/546503](https://doi.org/10.5402/2013/546503).
44. Herrera-Goepfert R, Vela-Chávez T, Carrillo-García A, Lizano-Soberón M, Amador-Molina A, Oñate-Ocaña LF, et al. High-risk human papillomavirus (HPV) DNA sequences in metaplastic breast carcinomas of Mexican women. *BMC Cancer.* 2013;**13**:445. doi: [10.1186/1471-2407-13-445](https://doi.org/10.1186/1471-2407-13-445). [PubMed: [24083491](https://pubmed.ncbi.nlm.nih.gov/24083491/)]. [PubMed Central: [PMC3852771](https://pubmed.ncbi.nlm.nih.gov/PMC3852771/)].
45. Aghdam MK, Nadji SA, Khoddami M, Dezfuli HB, Khademi Y. Epstein-Barr virus and breast carcinoma in Iran. *Jundishapur J Microbiol.* 2017;**10**(10):e12800. doi: [10.5812/jjm.12800](https://doi.org/10.5812/jjm.12800).
46. Golrokh Mofrad M, Kazeminezhad B, Faghihloo E. Prevalence of Epstein-Barr virus (EBV) in Iranian breast carcinoma patients. *Asian Pac J Cancer Prev.* 2020;**21**(1):133–7. doi: [10.31557/APJCP.2020.21.1.133](https://doi.org/10.31557/APJCP.2020.21.1.133). [PubMed: [31983175](https://pubmed.ncbi.nlm.nih.gov/31983175/)]. [PubMed Central: [PMC7294004](https://pubmed.ncbi.nlm.nih.gov/PMC7294004/)].
47. Torabizadeh Z, Nadji A, Naghshvar F, Nosrati A, Parsa M. Association between Epstein-Barr virus (EBV) and breast cancer. *Research in Molecular Medicine.* 2014;**2**(4):24–9. doi: [10.18869/acadpub.rmm.2.4.24](https://doi.org/10.18869/acadpub.rmm.2.4.24).
48. Makielski KR, Lee D, Lorenz LD, Nawandar DM, Chiu YF, Kenney SC, et al. Human papillomavirus promotes Epstein-Barr virus maintenance and lytic reactivation in immortalized oral keratinocytes. *Virology.* 2016;**495**:52–62. doi: [10.1016/j.virol.2016.05.005](https://doi.org/10.1016/j.virol.2016.05.005). [PubMed: [27179345](https://pubmed.ncbi.nlm.nih.gov/27179345/)]. [PubMed Central: [PMC4912861](https://pubmed.ncbi.nlm.nih.gov/PMC4912861/)].
49. Guidry JT, Scott RS. The interaction between human papillomavirus and other viruses. *Virus Res.* 2017;**231**:139–47. doi: [10.1016/j.virusres.2016.11.002](https://doi.org/10.1016/j.virusres.2016.11.002). [PubMed: [27826043](https://pubmed.ncbi.nlm.nih.gov/27826043/)]. [PubMed Central: [PMC5325789](https://pubmed.ncbi.nlm.nih.gov/PMC5325789/)].
50. Baffa R, Fassan M, Volinia S, O'Hara B, Liu CG, Palazzo JP, et al. MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. *J Pathol.* 2009;**219**(2):214–21. doi: [10.1002/path.2586](https://doi.org/10.1002/path.2586). [PubMed: [19593777](https://pubmed.ncbi.nlm.nih.gov/19593777/)].
51. Satapathy S, Batra J, Jeet V, Thompson EW, Punyadeera C. MicroRNAs in HPV associated cancers: Small players with big consequences. *Expert Rev Mol Diagn.* 2017;**17**(7):711–22. doi: [10.1080/14737159.2017.1339603](https://doi.org/10.1080/14737159.2017.1339603). [PubMed: [28597695](https://pubmed.ncbi.nlm.nih.gov/28597695/)].
52. Chen Y, Ma C, Zhang W, Chen Z, Ma L. Down regulation of miR-143 is related with tumor size, lymph node metastasis and HPV16 infection in cervical squamous cancer. *Diagn Pathol.* 2014;**9**:88. doi: [10.1186/1746-](https://doi.org/10.1186/1746-)

- 1596-9-88. [PubMed: 24774218]. [PubMed Central: PMC4039059].
53. PPoli V, Secli L, Avalle L. The microRNA-143/145 cluster in tumors: A matter of where and when. *Cancers*. 2020;**12**(3). doi: 10.3390/cancers12030708. [PubMed: 32192092]. [PubMed Central: PMC7140083].
54. Forte E, Salinas RE, Chang C, Zhou T, Linnstaedt SD, Gottwein E, et al. The Epstein-Barr virus (EBV)-induced tumor suppressor microRNA MiR-34a is growth promoting in EBV-infected B cells. *J Virol*. 2012;**86**(12):6889-98. doi: 10.1128/JVI.07056-11. [PubMed: 22496226]. [PubMed Central: PMC3393554].
55. Savitri E, Haryana MS. Expression of interleukin-8, interleukin-10 and Epstein-Barr viral-load as prognostic indicator in nasopharyngeal carcinoma. *Glob J Health Sci*. 2015;**7**(3):364-72. doi: 10.5539/gjhs.v7n3p364. [PubMed: 25948470]. [PubMed Central: PMC4802121].
56. Baker R, Dauner JG, Rodriguez AC, Williams MC, Kemp TJ, Hildesheim A, et al. Increased plasma levels of adipokines and inflammatory markers in older women with persistent HPV infection. *Cytokine*. 2011;**53**(3):282-5. doi: 10.1016/j.cyto.2010.11.014. [PubMed: 21167737]. [PubMed Central: PMC3033991].